

Shilpa Biologicals Pvt Ltd signs strategic development partnership with mAbTree Biologics AG for a novel immuno-oncology asset

Shilpa to undertake both development and commercial supply for mAbTree's novel checkpoint inhibitor

Basel Switzerland, and Karnataka India, March 17, 2025: [mAbTree Biologics AG](#) has signed an exclusive co-development and commercialization partnership with [Shilpa Biologicals Pvt Ltd](#). (a fully owned subsidiary of Shilpa Medicare Limited) for its novel biologic asset [a checkpoint inhibitor] for immuno-oncological applications.

Under the terms of the strategic agreement, Shilpa Biologicals will support both development – including clinical studies – as well as long-term commercial supply with GMP manufacturing. Additionally, Shilpa Group will provide mAbTree access to India and several global markets through its extensive partner network.

This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation and generation of strong immune responses against tumours akin to the well-established PD-1/PD-L1 blockade. While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest our novel target has as a highly attractive therapeutic potential in various immuno-oncological states both as a monotherapy and combinatorial therapy. This approach has the potential to convert cold tumours (poor immune cell infiltration) hot (good immune infiltration), suppress tumour metastasis and make the refractory tumors susceptible to chemotherapy as well and is applicable in various cancers, including lung cancer, head and neck squamous cell carcinoma, and hematologic malignancies.

“We are delighted to enter this strategic collaboration with mAbTree Biologics as we share a common vision to bring innovative solutions to address unmet medical needs around the globe especially in the field of oncology where Shilpa has had a long history of providing affordable innovative solutions” said Mr. Madhav Bhutada, Director, Shilpa Biologicals.

Shilpa Biologicals will utilize its large R&D teams – providing full-service capabilities from cell line development to GMP drug product manufacturing – with manufacturing and clinical supply conducted at its state-of-the art bio manufacturing facility at Dharwad, Karnataka.

Commenting on the co-development deal and its potential impact on patients, Dr Sridevi Khambhampaty, CEO Shilpa Biologicals: *“This novel therapy represents a new frontier in immuno-oncology, with the potential to expand treatment for patients who do not benefit from current immunotherapy options – so it’s potentially a massive breakthrough.”*

“mAbTree is excited to continue our strategic partnership with Shilpa Biologicals and our aim is to enable greater access to medicines for more patients across the world, especially focusing on India and ROW markets where access has been limited”, added Mr Raj Andhuvan, CEO mAbTree. “But what really impresses us about Shilpa is their commitment and scientific expertise. We look forward to rapidly advancing therapeutic options in the NBE space and to addressing emerging health challenges.”

[mAbTree Biologics](#) is a leading biotechnology company focused on the development of innovative therapies for cancer and other life-threatening diseases. With a commitment to scientific excellence and patient care, mAbTree Biologics interdisciplinary team of scientists, clinicians, and researchers aims to transform the landscape of cancer treatment through groundbreaking research and development.

Dr. Sridevi Khambhampaty (CEO) and the Shilpa Biologicals leadership- Ms. Shriya Khandwe (VP-BD) & team will be present at BIO-Europe Spring (March 17-19, Milan) and the Bioprocessing Summit Europe (March 18-20, Barcelona) to explore collaboration opportunities and discuss the advancement of biologics.

-ENDS-

Notes to editors

[About Shilpa Medicare](#)

[Shilpa Medicare](#) is a leading global pharmaceutical company specializing in contract development and manufacturing services for small and large molecules. With a strong emphasis on oncology and a growing presence in biologics, the company offers comprehensive solutions from discovery to commercial supply. Shilpa Medicare operates world-class R&D and manufacturing facilities, serving partners across North America, Europe, and Asia.

About Shilpa Biologicals Pvt Ltd

Shilpa Biologicals is a fully integrated biopharmaceutical company with a therapeutic focus on immunology, oncology and ophthalmics. The company's disruptive technology platforms enable patient access to high-quality, cutting-edge biopharmaceuticals in the global markets. The company currently has a pipeline of biosimilars at various stages of development including one commercialized product in the Indian market. The company is also catering to the growing demand from its global customers for high quality developmental and manufacturing work from its facility in Dharwad, Karnataka.

For media enquiries, please contact:

Alex Heeley or Nidhi Narain

De Facto Communications

T: [+44 \(0\) 203 735 8165](tel:+442037358165) / [+44 \(0\) 7834 785 764](tel:+442037834785764)

E: n.narain@defacto.co.uk / a.heeley@defacto.co.uk

Disclaimer : This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19) The Company and its management assumes no responsibility to publicly amend, modify or revise any statement, based on any subsequent development, information, or events, or otherwise.